Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Spyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 81 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-4.05. The mean expectation of eleven analysts for the quarter was for a loss of 99 cents per share. Wall Street expected results to range from $-1.29 to -61 cents per share.

• Reported revenue was zero​; analysts expected $2.10 million.

• Spyre Therapeutics Inc's reported EPS for the quarter was a loss of 81 cents​.

• The company reported a quarterly loss of $56.3 million.

• Spyre Therapeutics Inc shares had fallen by 18.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Spyre Therapeutics Inc is $65.00

This summary was machine generated from LSEG data February 27 at 09:42 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)